News

Orbit International Corp: Annual Results Show Positive Trends

Orbit International Corp: Annual Results Show Positive Trends

Orbit International Reports 2024 Financial Outcomes

In its annual financial results, Orbit International Corp. (OTC: ORBT) disclosed a net loss of $646,000 for 2024, which equates to a loss of $0.19 per share. This is an improvement compared to last year’s net loss of $1,147,000, or $0.34 per share. 2024 also saw an adjusted EBITDA of $159,000, representing $0.05 per diluted share, in contrast to the previous year’s loss of $407,000 ($0.12 loss per share).

Fourth Quarter Performance Overview

In the fourth quarter of 2024, the company reported a net loss of $252,000, or $0.08 per share, compared to a net loss of $339,000 in the same period of the prior year. This quarter’s adjusted EBITDA was $383,000, representing an increase compared to a loss of $206,000 year-over-year.

Highlights of Fourth Quarter vs. Previous Year

The financial performance for the fourth quarter demonstrated positive changes, highlighting:

  • Net sales increased to $8,708,000 from $7,173,000.
  • Gross margin improved to 34.6%, compared to 30.1% in the prior period.
  • The net loss was notably diminished, attributed to adjustments in operational costs and tax expenses.
  • Adjusted EBITDA reached $383,000 compared to a loss previously reported.

Annual Results and Fiscal Health

The total net sales for the year finished at $29,898,000, a rise from $27,556,000 in 2023. The gross margin also saw an uptick to 33.3%, compared to 31.7% last year. Notably, Orbit International has strengthened its financial position, boasting a current ratio of 2.9 to 1, indicative of solid liquidity.

Backlog Insights and Future Outlook

The backlog at year-end stood at $12 million, demonstrating a decline from $17.4 million the previous year, reflecting changing dynamics within the company’s contracts and project developments.

Commentary from Leadership

Mitchell Binder, President and CEO of Orbit International, expressed the company’s commitment to enhancing operational efficiency and managing costs effectively. He noted, "While our current year loss was influenced by a non-cash deferred tax expense, our operational results in the second half improved significantly as we focused on our subsidiary, Simulator Product Solutions LLC (SPS) and other strategic groups."

Anticipation of Future Growth

Looking ahead, Orbit International is poised to capitalize on its improved sales through its high-demand subsidiaries and is optimistic about maintaining a positive trajectory into 2025.

Frequently Asked Questions

What were Orbit International's total sales for 2024?

The company reported total sales of $29,898,000 for the fiscal year 2024.

How did the fourth quarter net loss compare to the previous year?

The fourth quarter net loss was $252,000, an improvement from a loss of $339,000 in the same quarter last year.

What contributed to the improved financial results for 2024?

Higher sales from the Simulator Product Solutions and improved gross margins contributed to the positive financial outcomes.

What is the current backlog for Orbit International as of December 31, 2024?

The backlog is reported at $12 million as of the end of 2024.

What plans does Orbit International have for 2025?

The company aims to enhance sales in their subsidiary groups and expects continued growth in bookings and operational efficiency.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Innovent's Seven Drugs Leap onto 2026 Reimbursement Chart

Updated Category News Views 223

A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...

Continue Reading
CARsgen's CAR-T Breakthrough on China's Insurance List

Updated Category News Views 154

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Continue Reading
Fluence Energy Faces Leadership Departures Amid Legal Woes

Updated Category News Views 122

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Continue Reading
ManuTech Center Set to Revolutionize Manufacturing Hub

Updated Category News Views 207

Jackson's Next Manufacturing Frontier Well, the folks down in Jackson, Michigan, are prepping to cut the red ribbon on something that's got me leaning forward in my seat. The Advanced Manufacturing Training Center (AMTC) is pulling out all the stops with their new ManuTech Prototyping Center. Yup, this center is about to become the playground for startups, manufacturers,...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 22

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
SmallRig Boosts Art-Driven Innovation in AI Era

Updated Category News Views 148

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

Continue Reading
WeFetch AI: A New Era in Barcode Precision

Updated Category News Views 225

WeFetch AI: What's in a Name? Forget about GreenCore Solutions Corp. We're talking about WeFetch AI Corp. now. They've just changed their name, fulfilling a bureaucratic tick as of November 13, 2026. But it ain't just a name change; it's a whole new ballgame in AI-driven commerce. AI Shopping Without the Guesswork We've all been there. You think you've ordered that...

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 155

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
EFICYENT Ventures to Connect at Singapore FinTech Fest

Updated Category News Views 150

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Continue Reading
Gaine Expands Healthcare Data Solutions Ahead of HLTH 2026

Updated Category News Views 233

Ever felt like healthcare systems are still stuck in a bygone era, struggling with data flinging through the void? Well, Gaine Technology is throwing down its gauntlet to change that narrative. Successful in pharmaceuticals and life sciences, they're turbocharging their Consent and Preference Management solution across the vast, tangled web of healthcare markets just in...

Continue Reading
les" class="btn" href="https://investorshangout.com/blog/news?page=2">More News Articles